Liu H., Li Y., Zhong L., et al. The research progress of circulating tumor DNA in breast cancer. Cancer Progress. 2019;17(10):1126–9.

Zhao Y., Wang J., Tang J., et al. Diagnostic criteria of vascular endothelial growth factor and microvessel density in breast cancer. J Vasc Endovasc Surg. 2018;4(5):68–72.

Group C breast cancer neoadjuvant therapy expert. Expert consensus on neoadjuvant therapy for breast cancer in China (2019 Edition). Chin J Cancer. 2019;29(5):390–400.

Sun L., Shen Z. New progress in diagnosis and treatment of elderly breast canceNo Title. Mod Oncol. 2016;24(22):3663–6.

Cheng Y., Ye H., Wang A., et al. Study on the effect of concurrent chemoradiotherapy and influencing factors of distant metastasis in advanced cervical squamous cell carcinoma. Hebei Med. 2016;38(19):2939–41.

Liu W., Li J., Wang T., et al. Efficacy and safety of anthracyclines combined with taxanes in neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2016;21(3):228–32.

Dong Y., Yang J., Xu M., et al. Analysis on death status and trend of female breast cancer in Wuxi City from 2009 to 2014. Pract Prev Med. 2017;24(1):12–4.

Hu Z., Yu Z. Investigation and analysis of radiotherapy after modified radical mastectomy in China. Chinese J Radiat Oncol. 2005;14(6):471–5.

Xuan L., Meng X., Sun B., et al. Clinical observation of docetaxel combined with bevacizumab in the treatment of multidrug-resistant breast cancer. Chinese J cancer Prev Treat. 2019;26(5):316–9.

Coudert B., Asselain B., Campone M., Spielmann M., Machiels J-P., Pénault-Llorca F., et al. Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial. Oncologist. 2012;17(7):900–9. doi:10.1634/theoncologist.2011-0442.

Zhang M., Luo F. Cardiovascular risk and Countermeasures of anthracyclines in the treatment of breast cancer. Cancer Res Clin. 2018;30(3):173–5.

Lei Y., Yan C., Xue Q., et al. Expression and clinical significance of VEGF and VEGFR in NSCLC. Cancer Progress. 2019;17(13):1573–5.

Zhang C., Jiang W. Expression and significance of serum lactoglobulin epidermal growth factor 8, carbohydrate antigen 125 and carcinoembryonic antigen in patients with breast cancer. Chinese Gen Clin. 2016;32(11):1020–2.

Burstein HJ., Bellon JR., Galper S., Lu HM., Kuter I., Taghian AG., et al. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006;64(2):496–504. doi:10.1016/j.ijrobp.2005.07.975.